Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERPS Trial: SABR in de Novo Oligometastatic Prostate Cancer
NCT05223803Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2022
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) and oligometastatic disease (OMD) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Failure-Free Survival at 2 years. Started Oct 2022; status: recruiting.
02
Conditions
prostate cancer (PCa)oligometastatic disease (OMD)
Beyond the preview
Go deeper on NCT05223803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223803.